Introduction
Histamine activation of the H 1 G protein-coupled receptor (GPCR) predominately activates Gα q protein and stimulation of phospholipase (PL) C to form inositol phosphates (IP) and diacylglycerol (DAG) signaling molecules [1] . This activity can present as respiratory distress, diarrhea, edema, and hypotension associated with an allergic response. In mammalian brain and adrenal gland, H 1 activation also can stimulate Gα s and adenylyl cyclase (AC) to form adenosine 3',5'-cyclic monophosphate (cAMP), a signaling molecule that modulates catecholamine neurotransmitter synthesis and release [1, 2] . Development of H 1 drugs has focused on antagonists for their anti-allergy effects. Recent understanding of the clinical importance of H 1 receptors in brain, however, suggests pharmacotherapeutic potential of H 1 /AC/cAMP agonists in neurodegenerative and neuropsychiatric disorders [3] . Like all mammalian GPCRs except bovine rhodopsin, the 3-dimensional structure of the human histamine H 1 receptor is unknown, compromising rational design of especially agonist H 1 receptor drugs. Here, human H 1 receptor mutagenesis and homology modeling results begin to delineate molecular determinants involved in histamine activation of H 1 -mediated PLC/IP/ versus AC/cAMP signaling.
Materials and methods
Histamine competitive displacement of the H 1 radioligand [ 3 H]-mepyramine was measured in membranes prepared from CHO-K1 cells and activity of PLC/IP or AC/cAMP formation was measured in whole CHO-K1 cells transiently expressing human cDNA for wild type (WT), K5.39A, or N5.46A point-mutated H 1 receptors, as previously described [1, 2, 4] . Western blots confi rmed receptors were expressed at comparable levels. Data were analyzed by nonlinear regression and expressed as mean percent basal condition. Measurements were in triplicate and experiments repeated using a new batch of transfected cells at least three times. The H 1 receptor model was built using Sybyl 7.2, based on homology to the bovine rhodopsin crystal structure (PDB code 1L9H). Model refi nement using molecular dynamics (MD) simulation in a lipid bilayer environment was performed with Gromacs 3.3.1 [5] . Manual docking of histamine to the H 1 model was guided by mutagenesis results. The histamine-H 1 receptor complex was energy minimized and subjected to a 100ps MD simulation with C atoms of the receptor constrained (ligand could move freely) using Amber force fi eld and Gasteiger-Huckel charges.
Results and discussion
Results for histamine binding and activation (PLC/IP vs. AC/ cAMP signaling) of the human WT H 1 receptor in comparison to K5.39A and N5.46A point-mutated H 1 receptors are summarized in the Table. At K5.39A and N5.46A H 1 receptors, respectively, histamine affi nity (K i ) is ~8-and ~40-times lower, and, potency (EC 50 ) to stimulate PLC/IP formation is ~9-and ~320-times lower, but, effi cacy (E max ) is not significantly (P > 0.05) affected, in comparison to WT receptors.
Correspondence to: R. G. Booth To help understand molecular details involved in agonist activated H 1 signaling for drug design, a 3-dimensional molecular model of the histamine-H 1 receptor complex (Figure) was built that incorporates the mutagenesis results reported above. The model indicates the known ionic interaction between the histamine terminal amine and H 1 D3.32, about 1.7 Å apart, required for binding and activation by histamine [6, 7] . Proposed hydrogen and electrostatic bonding of the histamine imidazole with H 1 residues K5.39 and N5.46, respectively, is consistent with previous studies [8] . Distance of the histamine imidazole unprotonated nitrogen to the H 1 K5.39 protonated nitrogen is 2.1 Å, favorable for H-bonding, and, the histamine imidazole is within 4 Å of the H 1 N5.46 amide, conducive to electrostatic binding.
These studies are the fi rst to report molecular interactions between histamine and the human H 1 receptor that infl uence PLC/IP vs. AC/cAMP signaling. Information learned here should prove useful to design agonist drugs that modulate brain H 1 /AC/cAMP signaling and catecholamine neurotransmission without untoward cardiovascular and respiratory effects associated with activation of H 1 /PLC/IP signaling. 
